Director David Shapiro granted 67,500 DSGN stock options (DSGN)

Q: What is the exercise price and expiration date of David Shapiro’s DSGN options?

Both option grants carry an exercise price of $10.64 per share and share the same expiration date of March 30, 2036 . These terms define the price and final date by which Shapiro can choose to exercise the options.

Q: How do the DSGN option grants to David Shapiro vest over time?

The 60,000-share option vests in equal monthly installments over 36 months following March 31, 2026 . The 7,500-share option vests in equal monthly installments over 12 months following the same date, according to the footnotes.

Q: Did David Shapiro buy or sell any DSGN shares in this Form 4?

The Form 4 shows no open-market purchases or sales of Design Therapeutics common stock. It only reports compensation-related stock option grants , classified as acquisitions of derivative securities rather than buy or sell transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Design Therapeutics director David Shapiro received new stock option awards, increasing his potential equity stake without any open-market trading. On March 31, 2026, he was granted options for 60,000 shares of common stock at an exercise price of $10.64 per share, expiring March 30, 2036. These options vest in equal monthly installments over 36 months following March 31, 2026. He also received a separate option for 7,500 shares at the same $10.64 exercise price, expiring March 30, 2036, vesting in equal monthly installments over 12 months following March 31, 2026. Both grants are reported as direct ownership and represent compensation awards rather than share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shapiro David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	60,000	$0.00	--
Grant/Award	Stock option (right to buy)	7,500	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 60,000 shares (Direct)

Footnotes (1)

The shares subject to the option will vest in equal monthly installments over 36 months following March 31, 2026. The shares subject to the option will vest in equal monthly installments over 12 months following March 31, 2026.

Key Figures

Option grant size: 60,000 options Second option grant size: 7,500 options Exercise price: $10.64 per share +3 more

6 metrics

Option grant size 60,000 options Covering 60,000 shares of common stock

Second option grant size 7,500 options Covering 7,500 shares of common stock

Exercise price $10.64 per share Exercise price for both option grants

Option expiration March 30, 2036 Expiration date for both grants

Vesting period (60,000 options) 36 months Equal monthly vesting after March 31, 2026

Vesting period (7,500 options) 12 months Equal monthly vesting after March 31, 2026

Key Terms

Stock option (right to buy), exercise price, vesting

3 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option will vest in equal monthly installments over 36 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shapiro David

(Last)

(First)

(Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD

CALIFORNIA

92011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$10.64	03/31/2026		A		60,000		⁽¹⁾	03/30/2036	Common Stock	60,000	$0	60,000	D
Stock option (right to buy)	$10.64	03/31/2026		A		7,500		⁽²⁾	03/30/2036	Common Stock	7,500	$0	7,500	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over 36 months following March 31, 2026.

2. The shares subject to the option will vest in equal monthly installments over 12 months following March 31, 2026.

	/s/ Mustapha Parekh, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did David Shapiro report in his latest Form 4 for DSGN?

David Shapiro reported receiving two stock option grants tied to Design Therapeutics common stock. One covers 60,000 shares and the other 7,500 shares, both with a $10.64 exercise price, expiring in 2036, and vesting monthly over multi-year schedules.

How many Design Therapeutics (DSGN) options were granted to David Shapiro?

David Shapiro was granted stock options covering a total of 67,500 shares of Design Therapeutics common stock. This consists of one grant for 60,000 shares and a second grant for 7,500 shares, each reported as direct derivative holdings in the filing.

What is the exercise price and expiration date of David Shapiro’s DSGN options?

Both option grants carry an exercise price of $10.64 per share and share the same expiration date of March 30, 2036. These terms define the price and final date by which Shapiro can choose to exercise the options.

How do the DSGN option grants to David Shapiro vest over time?

The 60,000-share option vests in equal monthly installments over 36 months following March 31, 2026. The 7,500-share option vests in equal monthly installments over 12 months following the same date, according to the footnotes.

Did David Shapiro buy or sell any DSGN shares in this Form 4?

The Form 4 shows no open-market purchases or sales of Design Therapeutics common stock. It only reports compensation-related stock option grants, classified as acquisitions of derivative securities rather than buy or sell transactions.